263 related articles for article (PubMed ID: 21172869)
1. IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection.
Lin JS; Kummer LW; Szaba FM; Smiley ST
J Immunol; 2011 Feb; 186(3):1675-84. PubMed ID: 21172869
[TBL] [Abstract][Full Text] [Related]
2. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.
Szaba FM; Kummer LW; Wilhelm LB; Lin JS; Parent MA; Montminy-Paquette SW; Lien E; Johnson LL; Smiley ST
Infect Immun; 2009 Oct; 77(10):4295-304. PubMed ID: 19620344
[TBL] [Abstract][Full Text] [Related]
3. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
4. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection.
Philipovskiy AV; Smiley ST
Infect Immun; 2007 Feb; 75(2):878-85. PubMed ID: 17118978
[TBL] [Abstract][Full Text] [Related]
6. Cell-mediated protection against pulmonary Yersinia pestis infection.
Parent MA; Berggren KN; Kummer LW; Wilhelm LB; Szaba FM; Mullarky IK; Smiley ST
Infect Immun; 2005 Nov; 73(11):7304-10. PubMed ID: 16239527
[TBL] [Abstract][Full Text] [Related]
7. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague.
Kumar D; Kirimanjeswara G; Metzger DW
Clin Vaccine Immunol; 2011 Nov; 18(11):1925-35. PubMed ID: 21880856
[TBL] [Abstract][Full Text] [Related]
10. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.
Sun W; Six D; Kuang X; Roland KL; Raetz CR; Curtiss R
Vaccine; 2011 Apr; 29(16):2986-98. PubMed ID: 21320544
[TBL] [Abstract][Full Text] [Related]
11. Protection against pneumonic plague following oral immunization with a non-replicating vaccine.
Jones A; Bosio C; Duffy A; Goodyear A; Schriefer M; Dow S
Vaccine; 2010 Aug; 28(36):5924-9. PubMed ID: 20600517
[TBL] [Abstract][Full Text] [Related]
12. Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.
Tiner BL; Sha J; Ponnusamy D; Baze WB; Fitts EC; Popov VL; van Lier CJ; Erova TE; Chopra AK
Clin Vaccine Immunol; 2015 Dec; 22(12):1255-68. PubMed ID: 26446423
[TBL] [Abstract][Full Text] [Related]
13. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague.
Davies ML; Biryukov SS; Rill NO; Klimko CP; Hunter M; Dankmeyer JL; Miller JA; Shoe JL; Mlynek KD; Talyansky Y; Toothman RG; Qiu J; Bozue JA; Cote CK
Front Immunol; 2024; 15():1397579. PubMed ID: 38835755
[TBL] [Abstract][Full Text] [Related]
15. Complete Protection Against
Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
Front Immunol; 2022; 13():793382. PubMed ID: 35154110
[TBL] [Abstract][Full Text] [Related]
16. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
[TBL] [Abstract][Full Text] [Related]
17. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
18. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
[TBL] [Abstract][Full Text] [Related]
19. Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection.
Parent MA; Wilhelm LB; Kummer LW; Szaba FM; Mullarky IK; Smiley ST
Infect Immun; 2006 Jun; 74(6):3381-6. PubMed ID: 16714568
[TBL] [Abstract][Full Text] [Related]
20. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
